FBXL5, also previously identified as an onco‐suppressor,[16, 26, 27] exhibits an adverse association with the survival of cancer patients.[28] Downregulation of FBXL5 has been shown to elevate intracellular ROS levels via iron overload, although it was unable to induce ferroptosis.[16] Our observations in NSCLC cells further underscore the dependency of ALKBH5 on FBXL5 to decrease intracellular ROS, thereby inhibiting oncogenic pathways and malignant phenotype. This evidence concerns the gene ALKBH5 and non-small cell lung carcinoma.